Empliciti vs. Xpovio

• Are Empliciti and Xpovio the Same Thing?
• What Are Possible Side Effects of Empliciti?
• What Are Possible Side Effects of Xpovio?
• What Is Empliciti?
• What Is Xpovio?
• What Drugs Interact with Empliciti?
• What Drugs Interact with Xpovio?
• How Should Empliciti Be Taken?
• How Should Xpovio Be Taken?

Empliciti (elotuzumab) and Xpovio (selinexor) are indicated in combination for the treatment of patients with multiple myeloma.

Empliciti is used in combination with lenalidomide and dexamethasone in patients who have received one to three prior therapies.

Xpovio is used in combination with dexamethasone in patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Empliciti is a SLAMF7-directed immunostimulatory antibody and Xpovio is a nuclear export inhibitor

Side effects of Empliciti and Xpovio that are similar include fatigue, diarrhea, constipation, upper respiratory tract infection, decreased appetite, vomiting, weight loss, and low white blood cell count.

Side effects of Empliciti that are different from Xpovio include fever, cough, tingling or numbness in the hands and feet, sore throat, runny or stuffy nose, pneumonia, pain in the extremities, headache, and cataracts.

Side effects of Xpovio that are different from Empliciti include low blood platelets, nausea, anemia, low blood sodium, and shortness of breath.

Both Empliciti and Xpovio may interact with other drugs.

Common side effects of Empliciti include:

• fatigue,
• diarrhea,
• fever,
• constipation,
• cough,
• tingling or numbness in the hands and feet,
• sore throat,
• runny or stuffy nose,
• upper respiratory tract infection,
• decreased appetite,
• pneumonia,
• pain in the extremities,
• headache,
• vomiting,
• weight loss,
• low white blood cell count (lymphocytopenia), and
• cataracts.

Tell your doctor if you have serious side effects of Empliciti including:

• anemia,
• blood clot in the lungs (pulmonary embolism), and
• acute kidney failure.

Common side effects of Xpovio include:

• low blood platelets,
• fatigue,
• nausea,
• anemia,
• decreased appetite,
• weight loss,
• diarrhea,
• vomiting,
• low blood sodium,
• low white blood cell counts,
• constipation,
• shortness of breath, and
• upper respiratory tract infection

Empliciti (elotuzumab) for injection is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

Xpovio (selinexor) is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Premedicate with dexamethasone, diphenhydramine, ranitidine, and acetaminophen. Empliciti may interact with other drugs. Tell your doctor all medications and supplements you use. Empliciti is not recommended for use during pregnancy; it may harm a fetus. It is unknown if Empliciti passes into breast milk. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended.

Tell your doctor all medications and supplements you use. Xpovio is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Xpovio and for one week after the last dose. It is unknown if Xpovio passes into breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended while using Xpovio and for at least one week after the last dose.

The dose of Empliciti given with lenalidomide and dexamethasone is 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter until disease progression or unacceptable toxicity.

The recommended starting dose of Xpovio is 80 mg in combination with dexamethasone taken orally on days 1 and 3 of each week. Xpovio may interact with other drugs.